Angola vs Latvia: Access to anti-retroviral drugs, male
Angola
52.0%
in 2024
Latvia
51.0%
in 2024
Angola rank
113th
Latvia rank
116th
Access to anti-retroviral drugs, male over time
- Angola
- Latvia
How they compare
Angola currently reports 52.0% against 51.0% in Latvia, a difference of 1.0%.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Latvia ahead.
Angola ranks 113th and Latvia ranks 116th of 141 countries.
Across the 3 decades both report, Angola averaged higher in 1 and Latvia in 2.
Head to head by decade
| Decade | Angola | Latvia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 2.6% | 3.3% | 0.7% | Latvia |
| 2010s | 23.6% | 22.3% | 1.3% | Angola |
| 2020s | 43.2% | 49.0% | 5.8% | Latvia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Angola or Latvia?
- Angola, at 52.0% against 51.0% in Latvia as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Angola and Latvia?
- 1.0%, with Angola ahead.
- How many years of comparable data are there for Angola and Latvia?
- 25 years are reported by both, from 2000 to 2024.
- How do Angola and Latvia rank globally for access to anti-retroviral drugs, male?
- Angola ranks 113th and Latvia ranks 116th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.